MedPath

The Role of Intranasal Corticosteroids in the Management of Chronic Idiopathic Urticaria with Positive Skin Prick Test to Airborne Allergens

Phase 3
Recruiting
Conditions
Chronic Idiopathic Urticaria.
Idiopathic urticaria
L50.1
Registration Number
IRCT20231126060193N1
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
69
Inclusion Criteria

Inclusion Criteria:Patients must be older than eighteen years.Patients must have a diagnosis of idiopathic urticaria and positive prick test results for airborne antigens.Patients should be selected from adult allergy clinics.Patients must give their informed consent to participate in the study.

Exclusion Criteria

Patients who are under treatment other than antihistamines by a doctor specializing in asthma and allergies.Patients who cannot participate during six months.Patients who had serious side effects due to corticosteroids before the start of the study.Patients who have serious side effects caused by the use of corticosteroids during the study period.Patients who experience serious side effects from corticosteroids during the study period.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome measures include the frequency and severity of urticaria symptoms, which are evaluated using valid scoring systems such as the Urticaria Activity Score and the Urticaria Severity Score. Timepoint: At the beginning of the study (before the start of the intervention) and six months after the start of the study. Method of measurement: Quality of life questionnaire related to chronic urticaria.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath